{"entity":{"id":"marco-herold","kind":"person","name":"Marco Herold","aka":[],"tldr":"Cancer biologist who leads the Olivia Newton-John Cancer Research Institute, the research arm of the Olivia Newton-John Cancer Wellness and Research Centre in Melbourne.","summary":"Professor Marco Herold is Chief Executive Officer of the Olivia Newton-John Cancer Research Institute (ONJCRI), the research institute embedded in the Olivia Newton-John Cancer Wellness and Research Centre, an Austin Health comprehensive cancer service in Heidelberg, Melbourne. He also heads the Blood Cancer and Immunotherapy Laboratory and La Trobe University's School of Cancer Medicine, and joined ONJCRI in 2023 from the Walter and Eliza Hall Institute. His research applies genome wide CRISPR screening to find drug resistance factors and targets that enhance immune therapies.","asOf":"2026-09-10","links":[{"label":"Source: ONJCRI our people page","url":"https://www.onjcri.org.au/our-people/"}],"tags":["leadership","clinician-scientist","immunotherapy","genome-editing"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wehi"],"pathways":[],"terms":["immunotherapy-term","leukaemia-type"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Olivia Newton-John Cancer Research Institute","institutionId":"onj-cancer-centre","specialisms":["Blood cancer","Cancer immunotherapy","CRISPR genome editing"],"profiles":[{"label":"ONJCRI profile","url":"https://www.onjcri.org.au/about/marco-herold/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herold+MJ%5BAuthor%5D"}],"papers":[{"title":"Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma","journal":"Nature Communications","year":2025,"doi":"10.1038/s41467-025-62615-y"},{"title":"Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responses","journal":"Cell Death & Differentiation","year":2023,"doi":"10.1038/s41418-023-01249-3"},{"title":"Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins","journal":"Cell Death & Differentiation","year":2025,"doi":"10.1038/s41418-025-01487-7"}],"orcid":"0000-0001-7539-7581"},"route":"/people/marco-herold/","neighbours":{"institution":[{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/"},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/"}],"term":[{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/"},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/"}]}}